Literature DB >> 8832674

In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate.

D Yoshida1, J M Piepmeier, A Teramoto.   

Abstract

OBJECTIVE: Several determinants of cell motility are highly dependent on the cytoskeleton, in particular, microtubules. To our knowledge, there have been no previous reports regarding the anti-invasive ability by an antimicro-tubule agent, estramustine phosphate (EMP), on glioblastoma cell lines. We investigated the modulated cell proliferation and invasiveness by EMP in vitro.
METHODS: We determined the relative survival rate by cell proliferation assay and the percent survival fraction by monotetrazolium assay. Furthermore, an invasion index was used to quantify the migrating and invasive potential of the human glioblastoma cell line, U87MG, in Boiden's chamber with reconstituted basement membrane (Matrigel; Collaborative Research, Lexington, MA).
RESULTS: We found that 0.5 mumol/L EMP had no effect in any of the assays. Concentrations of 1, 5, and 10 mumol/L demonstrated a concentration- and time-dependent depression in all of the assays. A range of drug concentration of EMP, 1 to 10 mumol/L, in which cell invasiveness was successfully inhibited, was comparable with antiproliferative capacity.
CONCLUSION: The data add to the findings that EMP not only offers selective antiproliferative activity against glioblastoma but also reduces invasiveness, consistent with its main mechanism of action. Such findings form the basis for the development of agents that use non-DNA targets for the treatment of glioblastomas and may improve control over tumor proliferation and invasion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8832674     DOI: 10.1097/00006123-199608000-00025

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  11 in total

Review 1.  Biological mechanisms of glioma invasion and potential therapeutic targets.

Authors:  B B Tysnes; R Mahesparan
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

2.  Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study.

Authors:  M Noha; D Yoshida; K Watanabe; A Teramoto
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

3.  Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study.

Authors:  Maode Wang; Daizo Yoshida; Shouxun Liu; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

4.  The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study.

Authors:  D Yoshida; M Noha; K Watanabe; T Bergenheim; R Henriksson; A Teramoto
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

5.  Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B.

Authors:  K Watanabe; D Yoshida; M Noha; A Teramoto
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

6.  Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study.

Authors:  D Yoshida; S Hoshino; T Shimura; H Takahashi; A Teramoto
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

7.  High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.

Authors:  Roger Henriksson; Annika Malmström; Per Bergström; Gertrud Bergh; Thomas Trojanowski; Lars Andreasson; Erik Blomquist; Sonny Jonsborg; Tomas Edekling; Pär Salander; Thomas Brännström; A Tommy Bergenheim
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

8.  Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2.

Authors:  D Yoshida; M Noha; K Watanabe; H Takahashi; Y Sugisaki; A Teramoto
Journal:  J Neurooncol       Date:  2001-08       Impact factor: 4.130

9.  Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Authors:  Howard Landy; Arnold Markoe; Priscilla Potter; Garrett Lasalle; Angela Marini; Niramol Savaraj; Isildinha Reis; Deborah Heros; Medhi Wangpaichitr; Lynn Feun
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

10.  Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent: in vitro study.

Authors:  D Yoshida; J M Piepmeier; T Bergenheim; R Henriksson; A Teramoto
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.